| |
Improve clinical outcomes by creating more flexible, patient-focused protocols that enhance enrollment and boost patient engagement with IQVIA Patient Centricity in Design. Get the fact sheet.
|
|
|
Transform the Industry with Your Innovation! Submissions are now open for the Fierce Life Sciences Innovation Awards. Click to submit your entry and learn more about the categories and criteria.
|
|
| By Angus Liu Pfizer is laying off 210 employees across two North Carolina manufacturing sites, including 150 people at the main facility involved in the recently failed DMD gene therapy program. |
|
|
|
By Nick Paul Taylor Bristol Myers Squibb had had a whiplash change of heart on its BCMA bispecific T-cell engager, halting further development months after filing to run a phase 3 trial. The Big Pharma disclosed the change of plan alongside a phase 3 win for a potential challenger to Regeneron, Sanofi and Takeda. |
By Conor Hale In the game of moneyed musical chairs, it’s clear the tempo has slowed. |
By Kevin Dunleavy Four months after Bayer handed pink slips to 90 staffers at its U.S. headquarters in Whippany, New Jersey, the company is laying off 70 more at the site, according to a state Worker Adjustment and Retraining Notification. |
|
September 25-27, 2024 | Philadelphia, PA Join the Fierce Clinical Summit, the premier event for clinical research and trial management. Explore topics in Clinical Operations, Quality, and DCT & Technology. Learn, network, and connect with peers to advance industry standards and innovations in clinical trials. Save up to $500 with Early Bird Rates. Register Now!
|
|
By James Waldron Earlier this month, Flagship Pioneering hinted that another Big Pharma may soon join its growing fleet of collaborators. Now, GSK has sailed into view. |
By Conor Hale The Alphabet company once synonymous with Silicon Valley's penchant for moonshot startup projects, Verily will now move its South San Francisco HQ to the "business-friendly" Dallas area, after it simplified its portfolio last year. |
By Nick Paul Taylor AbbVie could have the hottest cancer drug launch of 2025 on its hands. That is one takeaway from a recent ZoomRx survey, which found oncologists are more aware of and excited about AbbVie’s telisotuzumab-vedotin (Teliso-V) than any other investigational cancer candidate. |
By Kevin Dunleavy Bristol Myers Squibb CEO Chris Boerner said after seeing the final negotiated price for Eliquis that he is "increasingly confident" the company can navigate the impact of the IRA. |
By Zoey Becker The ruling from the Third Circuit Court of Appeals came the night before claimants in the talc litigation were set to vote on a sweeping $6.48 billion settlement proposal from J&J. |
By Conor Hale On a call with investors, President and CEO Kevin Sayer attributed part of the problem to a steep, unanticipated rise in the number of people obtaining rebates for its G7 continuous glucose monitor. |
By Darren Incorvaia Toxoplasma gondii is a protozoan parasite famous for its cunning ways. This microbial manipulator can only reproduce inside of cats, so, if it finds itself in another mammalian host, like a rat, it alters the rodent’s behavior to make it less fearful of felines. Now, researchers have devised a way to engineer this single-celled saboteur for good. |
Fierce podcastsDon’t miss an episode |
| | This week on "Podnosis," we dive into the topic of how to improve diversity and equity in dermatology. |
|
|---|
|
|
|
Wednesday, August 7, 2024 | 10am ET / 7am PT Demand for safe, cost-effective RNA manufacturing is increasing. Knowing how to effectively streamline processes and choose the right partners are critical to success. Join us as we explore the latest strategies and solutions to meet today’s increasing demands for safety and cost-effectiveness. Register now.
|
|
| WhitepaperThe pharmaceutical industry faces ongoing challenges as the average drug development cost has increased by 15%, to now exceed $2 billion among leading biopharma companies. Download this playbook to discover the future of BioPharma financial analysis. Sponsored by: Visible Alpha, now a part of S&P Global Market Intelligence |
| WhitepaperThis paper explores the costs of setting up a supply chain in Europe for a new biopharma therapy. It outlines key cost drivers & the various levers decision makers can use to affect those costs. Sponsored by: AIM |
| WhitepaperDownload the white paper to learn how this innovative solution can help optimize your mAb production processes. The findings demonstrate the system's robust capability to sustain strong cell growth and high productivity, facilitating a smooth transition from laboratory to production scale. Sponsored by: Thermo Fisher Scientific |
| WhitepaperSelf-amplifying RNAs (also known as self-replicating RNAs), or saRNAs, are increasing in popularity as a platform for vaccine development. Download to learn how to make a more streamlined and efficient manufacturing of self-amplifying RNAs. Sponsored by: TriLink |
| WhitepaperIn this white paper, Lonza experts delve into the common challenges encountered by ADC developers. They explore new drug product capabilities in relation to cytotoxic drug development and manufacturing, therefore fully completing Lonza’s integrated ADC offering. Further, they discuss how this end-to-end approach can significantly accelerate the timeline to investigational new drug filing and beyond. Read this white paper to learn more. Sponsored by: Lonza |
| WhitepaperThe definitive report on the state of our industry. Readers will gain an understanding of key indicators to monitor, future predictions, and guidance for investors and founders navigating the therapeutic enabling tools and services, healthtech and techbio sectors through 2024 and beyond. Sponsored by: AVANT BIO |
| WhitepaperThis study delved into the manufacturing costs of the three mRNA capping methods. It involved discussions with 30 subject matter experts engaged in mRNA therapeutic development across various companies in the US and the EU. Sponsored by: TriLink |
| ResearchLearn how a Top-10 Pharma company automated the extraction of oncology efficacy endpoints from scientific literature with high precision and recall using a combination of AI technologies. Sponsored by: IQVIA |
| WhitepaperSmall molecule active pharmaceutical ingredients (APIs) continue to grow more complex. Download the white paper to learn more about using synthesis and route design technology to approach API complexity. Sponsored by: Lonza |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
